This site is intended for Healthcare professionals.
×

Cipla gets 4 USFDA observations for Patalganga facility

................................ Advertisement ................................


business medical dialogues

New Delhi: Drug maker Cipla recently informed that the United States Food and Drug Administration (USFDA) conducted a routine cGMP (current Good Manufacturing Practice) inspection for both formulations and active pharmaceutical ingredients (APIs) at the company’s manufacturing facility in Patalganga. The inspection ended with 4 observations.

The inspection of the facilities was conducted from 4th to 13 November 2019.

Also Read: Cipla gets 7 USFDA observations for Bengaluru API unit

................................ Advertisement ................................

“The inspection ended with 4 observations, none of which were a repeat or related to data integrity,” Cipla said in a filing.

“The Company is committed to addressing these observations and will submit its response to the agency within the stipulated time, ” the company added.

................................ Advertisement ................................

Headquartered in Mumbai, Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.

................................ Advertisement ................................

Read Also: Cipla gets 12 USFDA observations for Goa facility

Spread the love

Author Details

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

Source: self
0 comment(s) on Cipla gets 4 USFDA observations for Patalganga facility

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted

    ................................ Advertisement ................................